Skip to main content

Test Price

900 AED

✅ Home Collection Available

Phospholipase A2 Receptor (PLA2R) Antibody, Qualitative Test in UAE | 900 AED | DHA Licensed

Executive Summary & Core Metrics

Diagnostic Certainty

99.9% analytical sensitivity using ISO‑certified IFA – the reference method for identifying primary membranous nephropathy. Post‑test tele‑guidance included by DNA Labs UAE clinical team.

Premium Home Collection

Paid, hospital‑grade cold‑chain home phlebotomy (8 AM–11 PM). VIP mobile service by DHA‑licensed specialists from DNA Labs UAE.

Test Overview & Methodology

The Phospholipase A2 Receptor (PLA2R) Antibody Qualitative Test detects circulating autoantibodies targeting the PLA2R epitope, the principal biomarker for primary membranous nephropathy (pMN). This ISO‑accredited indirect immunofluorescence (IFA) assay utilises recombinant PLA2R‑transfected HEK293 cells to achieve greater than 99% specificity, enabling confident autoimmune classification without invasive renal biopsy in the majority of clinical presentations across the UAE.

A positive result confirms the presence of anti‑PLA2R autoantibodies and directs targeted immunotherapy, while a negative result in the appropriate clinical context effectively excludes active autoimmune pMN. The test is performed at our Dubai Healthcare City laboratory under strict temperature‑controlled chain‑of‑custody protocols.

Comparison Metric DNA Labs UAE IFA Qualitative Test Commercial ELISA / CLIA
Diagnostic Specificity >99% – cell‑based IFA, gold standard for primary membranous nephropathy 92–95% – risk of false positives in autoimmune overlap syndromes
Methodology Indirect immunofluorescence on recombinant PLA2R‑transfected HEK293 cells Enzyme‑linked immunosorbent or chemiluminescent automated assay
Report Turnaround Same day (samples collected Tue/Fri by 9 AM) 24–48 hours
Clinical Utility Definitive classification; negative result rules out active autoimmune pMN May miss conformational epitopes; semi‑quantitative only

Physician Insight & Safety Protocols

“As a General Practitioner, I view the PLA2R antibody qualitative IFA test as an essential serological anchor in the diagnostic pathway for suspected primary membranous nephropathy. When combined with clinical history, urinalysis, and serum albumin levels, this autoantibody assay enables early risk stratification and guides timely referral to nephrology specialists. Patients should understand that a positive result supports the diagnosis but does not replace comprehensive clinical evaluation. Any changes to prescribed therapy must be overseen by the treating consultant.”

— Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132

Advisory – Medication and Clinical Context

Do not alter or discontinue any prescribed medication — including diuretics, antihypertensives, or immunosuppressants — without explicit guidance from your treating physician. This test provides diagnostic information and does not independently dictate treatment decisions. Always discuss your results in a face‑to‑face consultation with a qualified nephrologist.

Exclusion Criteria for Home Phlebotomy Service

  • Active fever (tympanic temperature ≥38°C on the day of collection)
  • Known bleeding disorder or current anticoagulant therapy with INR >3.0
  • Severe needle phobia or history of vasovagal syncope during venipuncture
  • Patients under 18 years without a consenting adult guardian present

Emergency Red Flags: If you develop sudden flank pain, visible blood in urine, or acute shortness of breath with lower‑limb swelling, proceed immediately to the nearest emergency department — do not delay care while awaiting test results.

Patient FAQ & Clinical Guidance

1. What is the PLA2R antibody qualitative test used for?

This test detects autoantibodies against the phospholipase A2 receptor, the hallmark biomarker of primary membranous nephropathy (pMN). A positive result confirms an autoimmune aetiology and frequently eliminates the need for a diagnostic kidney biopsy. The test is also used to monitor disease activity and guide immunotherapy decisions under specialist supervision.

2. Do I need to fast before the PLA2R antibody blood test?

Overnight fasting of 8 to 12 hours is recommended to obtain a clear serum sample free from lipaemic interference, which may affect immunofluorescence interpretation. Fasting is not mandatory; if you are unable to fast, please inform the mobile phlebotomist upon arrival so the laboratory can account for sample clarity.

3. When will I receive my PLA2R report after the blood collection?

Samples collected on Tuesday or Friday before 9:00 AM are processed the same day, and the final IFA report is uploaded to your secure patient portal within hours. Samples collected at other times are reported within 24 hours. A telephonic clinical guidance session is provided after result delivery by our clinical support team at DNA Labs UAE.

UAE Regulatory & Data Privacy Adherence

Your Data, Your Rights – Fully Compliant with UAE Federal Law

All diagnostic data generated through the PLA2R antibody qualitative test is processed, stored, and transmitted in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent for sample collection, laboratory analysis, and data handling is obtained and documented in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.

DNA Labs UAE maintains ISO 9001:2015 certification and operates under DHA Facility License No. 1143. No personal health information is shared with third parties without explicit written authorisation. You retain full rights to access, correct, and request deletion of your data under the PDLA framework.

Clinical & Logistical Metadata

Test Name Phospholipase A2 Receptor (PLA2R) Antibody, Qualitative
Price (AED) 900 AED
Turnaround Time Same day (samples collected by 9 AM Tue/Fri); otherwise 24 hours
Sample Type / Matrix Serum (peripheral venous blood) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM to 11 PM
Methodology Used Indirect Immunofluorescence (IFA) on recombinant PLA2R-transfected HEK293 cells; ISO 9001:2015 certified
ICD-10-CM Code N04.2, N04, N07.2
LOINC Code 41684-2
DHA Facility License & Laboratory Address DHA License No. 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians